Filtered By:
Condition: Diabetes Mellitus
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 239 results found since Jan 2013.

Epicardial adipose tissue volume predicts long term major adverse cardiovascular events in patients with Type 2 diabetes
CONCLUSION: EAT volume is an independent predictor of long-term MACE in patients with T2-DM without previous coronary events. EAT volume may be used additionally in risk stratification for MACE besides the well-known vascular risk factors in patients with T2-DM.PMID:33709918 | DOI:10.5543/tkda.2021.65635
Source: Turk Kardiyoloji Dernegi arsivi - March 12, 2021 Category: Cardiology Authors: Beg üm Uygur Ömer Çelik Ali R ıza Demir Muammer Karakayal ı Çağdaş Arslan Hafize Otcu Temur Deniz Alis Ceren Y ıldırım B üşra Çörekçioğlu Mehmet Ert ürk Source Type: research

Ten-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Patients with Type  2 Diabetes Mellitus Suffering from Left Main Coronary Disease: A Meta-Analysis
ConclusionsDuring a long-term follow-up time period of 10  years, PCI was associated with worse clinical outcomes compared to CABG in these patients with T2DM suffering from LMCD. However, a significantly higher risk of stroke was observed with CABG. This piece of information might be vital in order to carefully choose and prevent complications following revascularization in such patients.
Source: Diabetes Therapy - February 27, 2021 Category: Endocrinology Source Type: research

The prognostic implications of chronic kidney disease and anemia on long-term outcomes in patients undergoing percutaneous coronary intervention
In conclusion, the combined effects of both CKD and anemia on outcomes after PCI were worse than either of their individual effects.
Source: Heart and Vessels - February 19, 2021 Category: Cardiology Source Type: research

A comparison of clinical characteristics, the in-hospital course, and 12-month prognosis in women and men with chronic coronary syndromes.
Conclusions: Women and men with CCS differ in the incidence of risk factors and revascularization treatments. Men were found to have a higher frequency of 12-month death and composite endpoint follow-up. However, sex is not independent predictor of 12-month outcomes. PMID: 33463985 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - January 15, 2021 Category: Cardiology Authors: Duda-Pyszny D, Trzeciak P, Desperak P, Zembala M, Gąsior M Tags: Kardiol Pol Source Type: research

Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) after Percutaneous Coronary Intervention in High-Risk Patients with Diabetes Mellitus
The efficacy and safety of prolonged (>1-year) dual antiplatelet therapy (DAPT) duration in high-risk patients with diabetes mellitus (DM) undergoing PCI remain unknown. All patients undergoing PCI at Fuwai hospital between January 2013 and December 2013 were prospectively enrolled into the Fuwai PCI registry. 3696 high-risk diabetics patients with at least one additional atherothrombotic risk factor were screened for inclusion. The primary efficacy outcome was the composite of all-cause mortality, myocardial infarction, or stroke.
Source: The American Journal of Cardiology - December 4, 2020 Category: Cardiology Authors: Hao-Yu Wang, Zhong-Xing Cai, Dong Yin, Yue-Jin Yang, Wei-Hua Song, Ke-Fei Dou Source Type: research

Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population
ConclusionThis study demonstrates that RA is associated with an increased risk of HF, MI, stroke and coronary revascularization than found in the GP but without reaching the risk levels observed in DM patients.
Source: Rheumatology - September 27, 2020 Category: Rheumatology Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion in Native Coronary Arteries vs Saphenous Vein Grafts.
CONCLUSION: In this national cohort, CTO-PCI was performed in higher-risk patients, and was associated with more procedural complications but similar short-term or long-term mortality and in-hospital MACE. PMID: 32771995 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - August 13, 2020 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Authors: Calderone D, Capodanno D, Angiolillo DJ Abstract INTRODUCTION: - Ticagrelor is an antiplatelet agent acting through direct and reversible competitive inhibition of the platelet P2Y12 receptor. While the clinical merits of ticagrelor in patients who experienced an acute coronary syndrome are widely accepted, its role in stable coronary artery disease is less established. Recently, large-scale trials of ticagrelor have been published in this setting, including a trial in patients with diabetes mellitus (DM). AREAS COVERED: - This review aims to inform about recent findings on ticagrelor, by appraising th...
Source: Expert Review of Cardiovascular Therapy - July 15, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarc-tion Patients with Primary Percutaneous Coronary Intervention.
CONCLUSION: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI. PMID: 32598255 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - June 28, 2020 Category: Biotechnology Authors: Zhao B, Li GP, Peng JJ, Ren LH, Lei LC, Ye HM, Wang ZY, Zhao S Tags: Curr Pharm Biotechnol Source Type: research

Cardiovascular Outcomes Post Percutaneous Coronary Intervention in Patients with Obstructive Sleep Apnea and Type  2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionOSA was associated with a significant increase in all-cause mortality and MACEs post PCI in these patients with T2DM. Therefore, special care and continuous follow-up might be required for patients with T2DM with associated OSA after PCI. However, as a result of the limited number of participants, further larger studies would be required to confirm these hypotheses.
Source: Diabetes Therapy - June 25, 2020 Category: Endocrinology Source Type: research